EUVIMEDEUVIMED entdecken
Crossref

Clinical Outcomes of the PAUL® Glaucoma Implant for secondary glaucoma after vitreoretinal surgery

Constance Weber, Pascal Schipper, Wolfgang Walz, Kristin Raming, Sandrine Künzel, Frank G Holz, Raffael Liegl, Karl Mercieca

Ophthalmologica · 2025

DOI: 10.1159/000543748 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ophthalmologica, 2025. Verfasst von Constance Weber und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University of Bonn, Bonn, Germany. Hauptthemen laut MEDLINE: Vitreoretinal Surgery, Glaucoma Drainage Implants, Intraocular Pressure, Glaucoma. Die Arbeit wurde bisher 7-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To report clinical outcomes from a single-center cohort undergoing PAUL® Glaucoma Implant (PGI) surgery for secondary glaucoma after vitreoretinal surgery (VR).

Methods

Retrospective review of patients undergoing PGI surgery at the University Eye Hospital Bonn, Germany, from 04/2021 to 05/2023.

Results

33 eyes of 33 patients were included. Mean number of preoperative VR surgeries was 2 (1-4), the majority following retinal detachment (23 eyes, 69.7%). 18 eyes had previous silicone oil tamponade (54.4%). Complete (without drops) and qualified (with or without drops) success rates (95% CI) after one year were 69.7% (54.5–84.8) and 97% (90.9-100) for Criterion A (IOP≤21mmHg), 66.7% (51.5-81.8) and 87.9% (51.5-81.8) for Criterion B (IOP≤18mmHg), 54.5% (39.4-72.7) and 72.7% (54.5-87.9%) for Criterion C (IOP≤15mmHg) and 24.2% (9.1-39.4) and 30.3% (15.2-48.4) for Criterion D (IOP≤12mmHg) respectively. Mean IOP decreased from 25.64 mmHg (14-49 mmHg) to 13.59 mmHg (8-20 mmHg) (reduction of 41.1%) after 12 months with a reduction of IOP-lowering agents from 3.21 (1 – 5) to 0.38 (0 – 3). Seven eyes (21.2%) developed postoperative complications, most of which eventually resolved. Two eyes had a tube flushing because of high postoperative IOP with silicone oil obstruction. Postoperative non-glaucoma related procedures were performed in 10 eyes (24.4%). None of these led to high IOP or further complications in the postoperative phase.

Conclusions

PGI surgery is an effective procedure for reducing both IOP and topical therapy in patients with uncontrolled secondary glaucoma following vitreoretinal surgery. Non-glaucoma related procedures can be safely performed after PGI implantation with good IOP control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vitreoretinal SurgeryGlaucoma Drainage ImplantsIntraocular PressureGlaucomaVisual AcuityPostoperative ComplicationsHumansRetrospective StudiesMaleFemaleAgedMiddle AgedFollow-Up StudiesTreatment OutcomeProsthesis DesignAdultAged, 80 and overProsthesis Implantation

Stichwörter der Autor:innen

Glaucoma drainage deviceGlaucoma surgeryPAUL glaucoma implantSecondary glaucomaVitroretinal surgery

Autor:innen und Institutionen

  • Department of Ophthalmology, University of Bonn, Bonn, Germany.

Zitieren

APA

Weber, C., Schipper, P., Walz, W., Raming, K., Künzel, S., Holz, F. G., Liegl, R., & Mercieca, K. (2025). Clinical Outcomes of the PAUL® Glaucoma Implant for secondary glaucoma after vitreoretinal surgery. Ophthalmologica. https://doi.org/10.1159/000543748

Vancouver

Weber C, Schipper P, Walz W, Raming K, Künzel S, Holz FG, et al. Clinical Outcomes of the PAUL® Glaucoma Implant for secondary glaucoma after vitreoretinal surgery. Ophthalmologica. 2025. doi:10.1159/000543748

BibTeX
@article{Weber2025,
  author = {Weber, Constance and Schipper, Pascal and Walz, Wolfgang and Raming, Kristin and Künzel, Sandrine and Holz, Frank G and Liegl, Raffael and Mercieca, Karl},
  title = {Clinical Outcomes of the PAUL® Glaucoma Implant for secondary glaucoma after vitreoretinal surgery},
  journal = {Ophthalmologica},
  year = {2025},
  doi = {10.1159/000543748}
}
Kostenlos starten →